Management of Acute Coronary Syndrome
For patients with acute coronary syndrome, immediately initiate dual antiplatelet therapy with aspirin plus ticagrelor or prasugrel (preferred over clopidogrel) if undergoing PCI, continue for 12 months unless high bleeding risk, and perform urgent coronary angiography with revascularization based on presentation type. 1
Immediate Antiplatelet Strategy
The cornerstone of ACS management is dual antiplatelet therapy (DAPT):
- Start aspirin immediately in all patients unless contraindicated
- Add a P2Y12 inhibitor: Ticagrelor or prasugrel are superior to clopidogrel for patients undergoing PCI 1
- For non-STEMI patients with invasive strategy delayed >24 hours, upstream clopidogrel or ticagrelor may reduce major adverse cardiovascular events 1
- Default duration is 12 months for patients without high bleeding risk 1
Bleeding Risk Mitigation
When bleeding risk is elevated, three evidence-based strategies exist 1:
- Proton pump inhibitor for gastrointestinal bleeding risk
- Transition to ticagrelor monotherapy at 1 month post-PCI (if tolerated initially)
- Stop aspirin at 1-4 weeks post-PCI if long-term anticoagulation required, continue P2Y12 inhibitor (preferably clopidogrel)
Anticoagulation
Add parenteral anticoagulation with unfractionated heparin, low-molecular-weight heparin, bivalirudin, or fondaparinux 2
Revascularization Strategy
STEMI Presentation
- Perform PCI with stent placement immediately as first-line therapy
- Use fibrinolytic therapy only if PCI will be delayed >120 minutes 2
Non-STEMI Presentation
- Perform invasive coronary angiography with risk-based timing 3
- PCI is recommended; fibrinolytic therapy is not indicated 2
- Complete revascularization in hemodynamically stable patients with multivessel disease 3
- Culprit-lesion-only PCI initially if cardiogenic shock present 3
Cardiogenic Shock Management
Microaxial flow pump use is reasonable in selected patients with cardiogenic shock to reduce death, though complications (bleeding, limb ischemia, renal failure) are higher, requiring careful vascular access management and weaning 1
Anemia Management
Red blood cell transfusion to maintain hemoglobin of 10 g/dL may be reasonable in patients with ACS and acute or chronic anemia who are not actively bleeding 1
Additional Acute Pharmacotherapy
- High-intensity statin therapy initiated immediately
- Beta blockers for rate control and anti-ischemic effect 2
- ACE inhibitors for ventricular remodeling prevention 2
- Nitroglycerin and morphine for chest pain relief 2
- Oxygen only if hypoxemic
Post-Discharge Secondary Prevention
- Obtain fasting lipid panel 4-8 weeks after initiating or adjusting lipid-lowering therapy 1
- Add ezetimibe early when needed with statin 3
- Refer to cardiac rehabilitation (home-based programs acceptable for those unable to attend facility-based) 1
- PCSK9 inhibitors and low-dose colchicine are selective strategies for specific patients 3
- SGLT2 inhibitors and GLP-1 receptor agonists for established comorbid indications 3
Common Pitfall
The 2025 ACC/AHA guidelines emphasize that ticagrelor or prasugrel should be preferred over clopidogrel in PCI patients, yet clopidogrel remains widely used due to cost and familiarity. This represents suboptimal care unless bleeding risk specifically contraindicates the more potent agents 1.